176 related articles for article (PubMed ID: 38251600)
1. Pregnancy outcomes in women with primary Sjögren's syndrome: an analysis of data from the multicentre, prospective, GR2 study.
de Frémont GM; Costedoat-Chalumeau N; Lazaro E; Belkhir R; Guettrot-Imbert G; Morel N; Nocturne G; Molto A; Goulenok T; Diot E; Perard L; Ferreira-Maldent N; Le Besnerais M; Limal N; Martis N; Abisror N; Debouverie O; Richez C; Sobanski V; Maurier F; Sauvetre G; Levesque H; Timsit MA; Tieulié N; Orquevaux P; Bienvenu B; Mahevas M; Papo T; Lartigau-Roussin C; Chauvet E; Berthoux E; Sarrot-Reynauld F; Raffray L; Couderc M; Silva NM; Jourde-Chiche N; Belhomme N; Thomas T; Poindron V; Queyrel-Moranne V; Delforge J; Le Ray C; Pannier E; Mariette X; Le Guern V; Seror R;
Lancet Rheumatol; 2023 Jun; 5(6):e330-e340. PubMed ID: 38251600
[TBL] [Abstract][Full Text] [Related]
2. Characterisation of a high-risk profile for maternal thrombotic and severe haemorrhagic complications in pregnant women with antiphospholipid syndrome in France (GR2): a multicentre, prospective, observational study.
Murarasu A; Guettrot-Imbert G; Le Guern V; Yelnik C; Queyrel V; Schleinitz N; Ferreira-Maldent N; Diot E; Urbanski G; Pannier E; Lazaro E; Souchaud-Debouverie O; Orquevaux P; Belhomme N; Morel N; Chauvet E; Maurier F; Le Besnerais M; Abisror N; Goulenok T; Sarrot-Reynauld F; Deroux A; Pasquier E; de Moreuil C; Bezanahary H; Pérard L; Limal N; Langlois V; Calas A; Godeau B; Lavigne C; Hachulla E; Cohen F; Benhamou Y; Raffray L; de Menthon M; Tieulié N; Poindron V; Mouthon L; Larosa M; Eléfant E; Sentilhes L; Molto A; Deneux-Tharaux C; Costedoat-Chalumeau N;
Lancet Rheumatol; 2022 Dec; 4(12):e842-e852. PubMed ID: 38261392
[TBL] [Abstract][Full Text] [Related]
3. Identification of distinct subgroups of Sjögren's disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS cohorts.
Nguyen Y; Nocturne G; Henry J; Ng WF; Belkhir R; Desmoulins F; Bergé E; Morel J; Perdriger A; Dernis E; Devauchelle-Pensec V; Sène D; Dieudé P; Couderc M; Fauchais AL; Larroche C; Vittecoq O; Salliot C; Hachulla E; Le Guern V; Gottenberg JE; Mariette X; Seror R
Lancet Rheumatol; 2024 Apr; 6(4):e216-e225. PubMed ID: 38437852
[TBL] [Abstract][Full Text] [Related]
4. Obstetric and perinatal outcome in anti-Ro/SSA-positive pregnant women: a prospective cohort study.
Martínez-Sánchez N; Pérez-Pinto S; Robles-Marhuenda Á; Arnalich-Fernández F; Martín Cameán M; Hueso Zalvide E; Bartha JL
Immunol Res; 2017 Apr; 65(2):487-494. PubMed ID: 28138914
[TBL] [Abstract][Full Text] [Related]
5. Preconception clinical factors related to adverse pregnancy outcomes in patients with systemic lupus erythematosus or primary Sjögren's syndrome: a retrospective cohort study.
Fierro JJ; Prins JR; Verstappen GM; Bootsma H; Westra J; de Leeuw K
RMD Open; 2023 Aug; 9(3):. PubMed ID: 37652559
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
Bowman SJ; Fox R; Dörner T; Mariette X; Papas A; Grader-Beck T; Fisher BA; Barcelos F; De Vita S; Schulze-Koops H; Moots RJ; Junge G; Woznicki JN; Sopala MA; Luo WL; Hueber W
Lancet; 2022 Jan; 399(10320):161-171. PubMed ID: 34861168
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of adverse neonatal outcomes in pregnant women with positive anti-Ro/SSA and anti-La/SSB antibodies].
Zhang MY; Sun X
Zhonghua Fu Chan Ke Za Zhi; 2023 Nov; 58(11):804-810. PubMed ID: 37981765
[No Abstract] [Full Text] [Related]
9. Pregnancy and primary Sjögren's syndrome: management and outcomes in a multicentre retrospective study of 54 pregnancies.
Ballester C; Grobost V; Roblot P; Pourrat O; Pierre F; Laurichesse-Delmas H; Gallot D; Aubard Y; Bezanahary H; Fauchais AL
Scand J Rheumatol; 2017 Jan; 46(1):56-63. PubMed ID: 27191226
[TBL] [Abstract][Full Text] [Related]
10. Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ('Registry').
Erton ZB; Sevim E; de Jesús GR; Cervera R; Ji L; Pengo V; Ugarte A; Andrade D; Andreoli L; Atsumi T; Fortin PR; Gerosa M; Zuo Y; Petri M; Sciascia S; Tektonidou MG; Aguirre-Zamorano MA; Branch DW; Erkan D;
Lupus Sci Med; 2022 Jun; 9(1):. PubMed ID: 35701043
[TBL] [Abstract][Full Text] [Related]
11. Fetal outcome in women with primary Sjögren's syndrome. A retrospective case-control study.
Julkunen H; Kaaja R; Kurki P; Palosuo T; Friman C
Clin Exp Rheumatol; 1995; 13(1):65-71. PubMed ID: 7774105
[TBL] [Abstract][Full Text] [Related]
12. Lower frequency of focal lip sialadenitis (focus score) in smoking patients. Can tobacco diminish the salivary gland involvement as judged by histological examination and anti-SSA/Ro and anti-SSB/La antibodies in Sjögren's syndrome?
Manthorpe R; Benoni C; Jacobsson L; Kirtava Z; Larsson A; Liedholm R; Nyhagen C; Tabery H; Theander E
Ann Rheum Dis; 2000 Jan; 59(1):54-60. PubMed ID: 10627428
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of lupus anticoagulant, damage, and remission as predictors of pregnancy complications in systemic lupus erythematosus: the French GR2 study.
Larosa M; Le Guern V; Guettrot-Imbert G; Morel N; Abisror N; Morati-Hafsaoui C; Orquevaux P; Diot E; Doria A; Sarrot-Reynauld F; Limal N; Queyrel V; Souchaud-Debouverie O; Sailler L; Le Besnerais M; Goulenok T; Molto A; Pannier-Metzger E; Sentilhes L; Mouthon L; Lazaro E; Costedoat-Chalumeau N;
Rheumatology (Oxford); 2022 Aug; 61(9):3657-3666. PubMed ID: 35015828
[TBL] [Abstract][Full Text] [Related]
14. Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome Registry.
Dumusc A; Ng WF; James K; Griffiths B; Price E; Pease C; Emery P; Lanyon P; Jones A; Bombardieri M; Sutcliffe N; Pitzalis C; Gupta M; McLaren J; Cooper A; Giles I; Isenberg D; Saravanan V; Coady D; Dasgupta B; McHugh N; Young-Min S; Moots R; Gendi N; Akil M; Barone F; Fisher B; Rauz S; Richards A; Bowman S
Swiss Med Wkly; 2018; 148():w14588. PubMed ID: 29442344
[TBL] [Abstract][Full Text] [Related]
15. Utility of the EULAR Sjögren syndrome disease activity index in Japanese children: a retrospective multicenter cohort study.
Iwata N; Tomiita M; Kobayashi I; Inoue Y; Nonaka Y; Okamoto N; Umebayashi H; Hara R; Ito Y; Sato Y; Mori M
Pediatr Rheumatol Online J; 2020 Sep; 18(1):73. PubMed ID: 32943063
[TBL] [Abstract][Full Text] [Related]
16. Effect of Sjögren's syndrome on maternal and neonatal outcomes of pregnancy.
Elliott B; Spence AR; Czuzoj-Shulman N; Abenhaim HA
J Perinat Med; 2019 Aug; 47(6):637-642. PubMed ID: 31287800
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of ultrasound-indicated cerclage in twin pregnancies: a retrospective case-control study matched by cervical length.
Qiu L; Lv M; Chen C; Li J; Zhao B; Luo Q
Am J Obstet Gynecol MFM; 2023 Mar; 5(3):100847. PubMed ID: 36638868
[TBL] [Abstract][Full Text] [Related]
18. Primary Sjögren's syndrome and pregnancy: A report of 18 cases.
Demarchi J; Papasidero SB; Klajn D; Alba P; Babini AM; Durigan V; Gobbi C; Raiti L
Reumatol Clin (Engl Ed); 2019; 15(2):109-112. PubMed ID: 28844688
[TBL] [Abstract][Full Text] [Related]
19. Pregnancy and fetal outcome in women with primary Sjogren's syndrome compared with women in the general population: a nested case-control study.
Hussein SZ; Jacobsson LT; Lindquist PG; Theander E
Rheumatology (Oxford); 2011 Sep; 50(9):1612-7. PubMed ID: 21531959
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial.
Dörner T; Kaul M; Szántó A; Tseng JC; Papas AS; Pylvaenaeinen I; Hanser M; Abdallah N; Grioni A; Santos Da Costa A; Ferrero E; Gergely P; Hillenbrand R; Avrameas A; Cenni B; Siegel RM
Ann Rheum Dis; 2024 Feb; 83(3):360-371. PubMed ID: 37932009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
